Thousand Oaks, CA, United States of America

Hui-Quan Han

This inventor holds 14 USPTO granted patents and 1 published patent application, primarily in Ubiquitin Ligase Research. Top assignees: Amgen Inc., Atara Biotherapeutics, Inc.. Active years: 2004-2019.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hui-Quan Han. Retrieved from https://idiyas.com/inventor/hui-quan-han

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 14 (Patent Applications = 1)

% Patents Active = 64.3

Average Co-Inventor Count = 3.0

ph-index = 9

Forward Citations = 285(Granted Patents)

Company Filing History:

Atara Biotherapeutics, Inc.

patents

Years Active: 2004-2019

Loading Chart...

Areas of Expertise:

Activin Receptor

Ubiquitin Ligase

Polypeptides

Nucleic Acid

Antibodies

Biotechnology

Protein Engineering

Molecular Biology

Gene Expression

Therapeutics

Variant Proteins

Biopharmaceuticals

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10407487 - Variant activin receptor (2019-09-10),

2. 9809638 - Variant activin receptor (2017-11-07),

3. 9447165 - Variant activin IIB receptor (2016-09-20),

4. 8753627 - Anti-activin a antibodies and uses thereof (2014-06-17),

5. 8716459 - Isolated nucleic acid molecules encoding variant activin receptor polypeptides (2014-05-06),

6. 8501678 - Variant activin receptor polypeptides and uses thereof (2013-08-06),

7. 8309082 - Anti-activin A antibodies and uses thereof (2012-11-13),

8. 7994291 - Human E3α ubiquitin ligase family (2011-08-09),

9. 7947646 - Variant activin receptor polypeptides (2011-05-24),

10. 7745586 - Human E3α ubiquitin ligase family (2010-06-29),

11. 7422847 - Human E3α ubiquitin ligase family (2008-09-09),

12. 7220547 - Human E3α ubiquitin ligase family (2007-05-22),

13. 7179625 - Human E3α ubiquitin ligase family (2007-02-20),

14. 6706505 - Human E3&agr; ubiquitin ligase family (2004-03-16),

Title: Hui-Quan Han: Innovator in Muscle-Wasting Treatments

Introduction

Hui-Quan Han is a prominent inventor based in Thousand Oaks, CA (US). He has made significant contributions to the field of biotechnology, particularly in developing treatments for muscle-wasting diseases. With a total of 14 patents to his name, Han's work has the potential to impact many lives.

Latest Patents

One of Han's latest patents involves the development of variant activin IIB soluble receptor polypeptides and proteins. These innovative proteins are capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The invention also includes polynucleotides, vectors, and host cells that can produce these variant polypeptides and proteins. Furthermore, the patent outlines compositions and methods for treating muscle-wasting and other related diseases and disorders.

Career Highlights

Throughout his career, Hui-Quan Han has worked with notable companies such as Amgen Inc. and Atara Biotherapeutics, Inc. His experience in these organizations has allowed him to refine his expertise in biotechnology and contribute to groundbreaking research.

Collaborations

Han has collaborated with several talented individuals in his field, including Keith Soo-Nyung Kwak and Xiaolan Zhou. These partnerships have fostered innovation and have been instrumental in advancing his research.

Conclusion

Hui-Quan Han is a distinguished inventor whose work in developing treatments for muscle-wasting diseases showcases his dedication to improving health outcomes. His innovative patents and collaborations highlight his significant contributions to biotechnology.

Profile summary based on public USPTO records.

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

1 patent pending: